IOL master more accurate in silicone oil-filled eyes

Article

The IOL master is more accurate than A-scan immersion biometry in silicone oil (SO)-filled eyes.

The IOL master is more accurate than A-scan immersion biometry in silicone oil (SO)-filled eyes, claims a study in Eye.

Dr P. Kunavisarut et al., Department of Ophthalmology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, conducted a prospective, consecutive, non-randomized investigation on 34 SO-filled eyes of 34 patients. All patients underwent a pars plana vitrectomy with SO removal and cataract surgery, as well as IOL implantation.

Axial length (AXL) was measured before SO removal using both A-scan immersion and IOL master. AXL was also measured three months after SO removal using IOL master. The accuracy of both techniques was determined by a mean postoperative AXL and reliability was determined by mean actual postoperative refractive error.

The preoperative mean AXL was 23.91±0.24 mm and 23.71±0.59 mm by the IOL master and A-scan immersion, respectively. The IOL master gave a postoperative mean AXL of 23.90±0.23 mm, which was statistically significant, compared with A-scan immersion.

At a range of −14.62 to 16.41 D predictive postoperative refractive error was greater in A-scan immersion, which was a statistically significant difference compared to the IOL master.

Overall, the IOL master is more accurate and has less deviation in predictive postoperative refractive error then A-scan immersion in SO-filled eyes.

The abstract can be read here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.